Harmony Biosciences Holdings, Inc.
HRMYNASDAQHealthcare● Active
$32.31
+$0.11(+0.33%)
Market Cap$1.9B
P/E Ratio—
52W High$40.87
52W Low$25.52
Harmony Biosciences Holdings, Inc. (HRMY) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
HRMY · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
$0.55
Est. $0.76 · -27.6%
Revenue
$0.22B
Est. $0.22B · -2.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
HRMY reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | $0.87 | — | — | — | $0.24B | — |
| ▼ Q2 FY2026 | May 7, 2026 | $0.76 | $0.55 | -27.6% | $0.22B | $0.22B | -2.5% |
| ▼ Q1 FY2026 | Feb 24, 2026 | $0.84 | $0.38 | -54.8% | $0.24B | $0.24B | +1.4% |
| ▼ Q4 FY2025 | Nov 4, 2025 | $0.92 | $0.87 | -5.4% | $0.24B | $0.24B | -0.2% |
| ▼ Q3 FY2025 | Aug 5, 2025 | $0.78 | $0.68 | -12.8% | $0.20B | $0.22B | -8.9% |
| ▲ Q2 FY2025 | May 6, 2025 | $0.59 | $0.78 | +32.2% | $0.18B | $0.21B | -10.3% |
| ▲ Q1 FY2025 | Feb 25, 2025 | $0.74 | $0.85 | +14.9% | $0.20B | $0.18B | +9.9% |
| ▲ Q4 FY2024 | Oct 29, 2024 | $0.67 | $0.79 | +17.9% | $0.19B | $0.20B | -6.3% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
$0.87
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
$0.55
EPS Est.
$0.76
EPS Surpr.
-27.6%
Revenue
$0.22B
Q1 FY2026
Feb 24, 2026Miss
EPS Actual
$0.38
EPS Est.
$0.84
EPS Surpr.
-54.8%
Revenue
$0.24B
Q4 FY2025
Nov 4, 2025Miss
EPS Actual
$0.87
EPS Est.
$0.92
EPS Surpr.
-5.4%
Revenue
$0.24B
Q3 FY2025
Aug 5, 2025Miss
EPS Actual
$0.68
EPS Est.
$0.78
EPS Surpr.
-12.8%
Revenue
$0.20B
Q2 FY2025
May 6, 2025Beat
EPS Actual
$0.78
EPS Est.
$0.59
EPS Surpr.
+32.2%
Revenue
$0.18B
Q1 FY2025
Feb 25, 2025Beat
EPS Actual
$0.85
EPS Est.
$0.74
EPS Surpr.
+14.9%
Revenue
$0.20B
Q4 FY2024
Oct 29, 2024Beat
EPS Actual
$0.79
EPS Est.
$0.67
EPS Surpr.
+17.9%
Revenue
$0.19B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $1.07 | $1.14 | $1.17 | 1 |
| Q3 FY2027 | $0.92 | $0.97 | $1.00 | 1 |
| Q2 FY2027 | $0.91 | $0.96 | $1.00 | 1 |
| Q1 FY2027 | $0.74 | $0.79 | $0.81 | 1 |
| Q4 FY2026 | $0.98 | $1.04 | $1.07 | 1 |
| Q3 FY2026 | $0.85 | $0.98 | $1.20 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.3B | $0.3B | $0.3B | 3 |
| Q3 FY2027 | $0.3B | $0.3B | $0.3B | 3 |
| Q2 FY2027 | $0.3B | $0.3B | $0.3B | 3 |
| Q1 FY2027 | $0.2B | $0.3B | $0.3B | 4 |
| Q4 FY2026 | $0.3B | $0.3B | $0.3B | 4 |
| Q3 FY2026 | $0.3B | $0.3B | $0.3B | 7 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -27.6% | $32.78 | $31.42 | -4.15% |
| ▼ Q1 FY2026 | Feb 24, 2026 | -54.8% | $26.87 | $28.19 | +4.91% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -5.4% | $29.33 | $30.72 | +4.74% |
| ▼ Q3 FY2025 | Aug 5, 2025 | -12.8% | $35.54 | $34.94 | -1.69% |
| ▲ Q2 FY2025 | May 6, 2025 | +32.2% | $29.96 | $32.05 | +6.98% |
| ▲ Q1 FY2025 | Feb 25, 2025 | +14.9% | $34.18 | $36.97 | +8.16% |
| ▲ Q4 FY2024 | Oct 29, 2024 | +17.9% | $35.75 | $41.49 | +16.06% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +433.3% | $30.92 | $32.83 | +6.18% |
Q2 FY2026-4.15%
Report Date
May 7, 2026
EPS Beat/Miss
-27.6%
Price Before
$32.78
Price After
$31.42
Q1 FY2026+4.91%
Report Date
Feb 24, 2026
EPS Beat/Miss
-54.8%
Price Before
$26.87
Price After
$28.19
Q4 FY2025+4.74%
Report Date
Nov 4, 2025
EPS Beat/Miss
-5.4%
Price Before
$29.33
Price After
$30.72
Q3 FY2025-1.69%
Report Date
Aug 5, 2025
EPS Beat/Miss
-12.8%
Price Before
$35.54
Price After
$34.94
Q2 FY2025+6.98%
Report Date
May 6, 2025
EPS Beat/Miss
+32.2%
Price Before
$29.96
Price After
$32.05
Q1 FY2025+8.16%
Report Date
Feb 25, 2025
EPS Beat/Miss
+14.9%
Price Before
$34.18
Price After
$36.97
Q4 FY2024+16.06%
Report Date
Oct 29, 2024
EPS Beat/Miss
+17.9%
Price Before
$35.75
Price After
$41.49
Q3 FY2024+6.18%
Report Date
Aug 6, 2024
EPS Beat/Miss
+433.3%
Price Before
$30.92
Price After
$32.83
Avg Beat Reaction+9.34%
Avg Miss Reaction+0.95%
Beat Rate4 / 8 quarters
Largest Move+16.06% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: HRMY ends December
Harmony Biosciences Holdings, Inc. (HRMY) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $0.55 — missing the analyst consensus of $0.76 by -27.6%. The next HRMY earnings date is expected around September 1, 2026.
Each quarter, investors track HRMY earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. HRMY revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
HRMY's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
HRMY earnings · 5 questionsHarmony Biosciences Holdings, Inc.'s next earnings report is expected around September 1, 2026. HRMY typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; HRMY historically reports after market close (AMC).
HRMY earnings datewhen is HRMY earningsHRMY next earnings datewhen does HRMY report earningsHRMY earnings calendar
▸ Source: FMP · Harmony Biosciences Holdings, Inc. SEC filings · US GAAP · Harmony Biosciences Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026